---
title: "Teva Pharmaceuticals reports completion of phase 3 trial for Olanzapine LAI in Schizophrenia"
date: "2025-02-10 10:15:18"
summary: "The pivotal clinical phase 3 trial for the olanzapine Long-Acting Injectable in schizophrenia has been completed, Medincell’s partner Teva Pharmaceuticals (NYSE:TEVA) said, who finances and pilots the regulatory development of the product (mdc-TJK / TEV-'749). Medincell to receive a $5 million development milestone payment from Teva (NYSE:TEVA) with SOLARIS study..."
categories:
  - "seekalpha"
lang:
  - "en"
translations:
  - "en"
tags:
  - "seekalpha"
menu: ""
thumbnail: "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1316030674/image_1316030674.jpg"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

* The pivotal clinical phase 3 trial for the olanzapine Long-Acting Injectable in schizophrenia has been completed, Medincell’s partner Teva Pharmaceuticals (NYSE:[TEVA](https://seekingalpha.com/symbol/TEVA "Teva Pharmaceutical Industries Limited")) [said](https://seekingalpha.com/pr/19996192-completion-of-the-pivotal-phase-3-trial-for-olanzapine-lai-in-schizophrenia-conducted-by-teva "said"), who finances and pilots the regulatory development of the product (mdc-TJK / TEV-'749).
* Medincell to receive a $5 million development milestone payment from Teva (NYSE:[TEVA](https://seekingalpha.com/symbol/TEVA "Teva Pharmaceutical Industries Limited")) with SOLARIS study completion.
* “Our partner is advancing the clinical development of the olanzapine LAI with plans for regulatory submission in the US,” Richard Malamut, Chief Medical Officer at Medincell said.

[seekalpha](https://seekingalpha.com/news/4405439-teva-pharmaceuticals-reports-completion-of-phase-3-trial-for-olanzapine-lai-in-schizophrenia)
